These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. Adams M; Breckler L; Stevens P; Thom J; Baker R; Oostryck R Haematologica; 2004 Aug; 89(8):985-90. PubMed ID: 15339683 [TBL] [Abstract][Full Text] [Related]
3. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation. Lean SY; Ellery P; Ivey L; Thom J; Oostryck R; Leahy M; Baker R; Adams M Haematologica; 2006 Oct; 91(10):1360-6. PubMed ID: 17018385 [TBL] [Abstract][Full Text] [Related]
4. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. Forastiero RR; Martinuzzo ME; Broze GJ J Thromb Haemost; 2003 Apr; 1(4):718-24. PubMed ID: 12871406 [TBL] [Abstract][Full Text] [Related]
5. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. Yang YH; Hwang KK; FitzGerald J; Grossman JM; Taylor M; Hahn BH; Chen PP J Immunol; 2006 Dec; 177(11):8219-25. PubMed ID: 17114499 [TBL] [Abstract][Full Text] [Related]
6. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Salemink I; Blezer R; Willems GM; Galli M; Bevers E; Lindhout T Thromb Haemost; 2000 Oct; 84(4):653-6. PubMed ID: 11057865 [TBL] [Abstract][Full Text] [Related]
7. Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? de Medeiros DM; Silva CA; Bueno C; Ribeiro AC; Viana Vdos S; Carvalho JF; Bonfa E Lupus; 2014 Nov; 23(13):1412-6. PubMed ID: 24961747 [TBL] [Abstract][Full Text] [Related]
8. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Iversen N; Lindahl AK; Abildgaard U Thromb Res; 2002 Jan; 105(1):33-6. PubMed ID: 11864704 [TBL] [Abstract][Full Text] [Related]
9. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306 [TBL] [Abstract][Full Text] [Related]
10. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Jacobsen EM; Sandset PM; Wisløff F Thromb Res; 1999 May; 94(4):213-20. PubMed ID: 10336236 [TBL] [Abstract][Full Text] [Related]
11. Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Artim-Esen B; Pericleous C; Mackie I; Ripoll VM; Latchman D; Isenberg D; Rahman A; Ioannou Y; Giles I Arthritis Res Ther; 2015 Mar; 17(1):47. PubMed ID: 25890027 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. Chowdary P Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491 [TBL] [Abstract][Full Text] [Related]
13. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus. Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532 [TBL] [Abstract][Full Text] [Related]
15. Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. Artim-Esen B; Smoktunowicz N; McDonnell T; Ripoll VM; Pericleous C; Mackie I; Robinson E; Isenberg D; Rahman A; Ioannou Y; Chambers RC; Giles I Sci Rep; 2017 Sep; 7(1):10788. PubMed ID: 28883515 [TBL] [Abstract][Full Text] [Related]
16. Role of exosite binding modulators in the inhibition of Fxa by TFPI. Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136 [TBL] [Abstract][Full Text] [Related]
17. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Meneghel L; Ruffatti A; Gavasso S; Tonello M; Mattia E; Spiezia L; Tormene D; Hoxha A; Fedrigo M; Simioni P Clin Chim Acta; 2015 Jun; 446():201-5. PubMed ID: 25935129 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome. Zhang S; Wu Z; Li J; Wen X; Li L; Zhang W; Zhao J; Zhang F; Li Y Clin Rheumatol; 2017 Feb; 36(2):407-412. PubMed ID: 28000012 [TBL] [Abstract][Full Text] [Related]
20. Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex. Iversen N; Strekerud FG; Abildgaard U Blood Coagul Fibrinolysis; 2000 Oct; 11(7):591-8. PubMed ID: 11085278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]